Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9b442f17c57e6903e584b8486085ac9 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-02 |
filingDate |
2001-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a279a97a025a6ec519a4cd9a848efc47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4851da1053db2ffb9046b6b2d7973b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d95953dd253d2e8024e7129fb46c771e |
publicationDate |
2002-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-0212524-A2 |
titleOfInvention |
Adenovirus e1b-55k single amino acid mutants and methods of use |
abstract |
Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108136047-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022010946-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5006045-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2006036004-A1 |
priorityDate |
2000-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |